Prof. Graham Richards has been elected a Fellow of the Royal Society
Oxford Drug Design Chairman and Co-founder Prof. W. Graham Richards has been elected a Fellow of the Royal Society. Fellowship is awarded […]
Prof. Graham Richards awarded the Richard J. Bolte Sr. Award for Supporting Industries
Oxford Drug Design Chairman and Co-founder Prof. W. Graham Richards has been awarded the Richard J. Bolte Sr. Award for Supporting Industries. […]
Oxford Drug Design attends the Joint UK-QSAR/MGMS meeting
Oxford Drug Design attended the joint UK-QSAR/Molecular Graphics and Modelling Society (MGMS) conference on the theme of “Structure Activity Relationships”. Dr Grace […]
Oxford Drug Design in Chemistry World
Oxford Drug Design has contributed to an article in the March edition of Chemistry World. The article, entitled “Countdown to the last […]
N-Leucinyl Benzenesulfonamides as LeuRS Inhibitors
ODD scientists and collaborators have published a research paper describing the discovery of a new class of aminoacyl-tRNA synthetase inhibitors, N-Leucinyl benzenesulfonamides. […]
Oxford Drug Design attends Medicines Discovery Catapult’s Antimicrobial Resistance Workshop
Dr. Michael Charlton presented a review of literature analyses of the physical properties of antibacterial compounds. This included an emphasis on our […]
CARTNET Begins – Oxford Drug Design starts work on AMR training network
Oxford Drug Design has started work on a new €3.4 Million Horizon 2020 Marie Curie European Training Network – CARTNET, “Combating Antimicrobial Resistance […]
Oxford Drug Design present on novel LeuRS inhibitors at aaRS2017
Dr. Michael Charlton and Dr. Grace Edmund recently reported our work in the design of novel compounds to target the synthetic active […]
Oxford Drug Design win EU support for antibacterial research
The European Commission has awarded 3.4 Million Euro under the Horizon 2020 programme to a new Marie Curie European Training Network – CARTNET, […]
Prof. David Livermore joins the Oxford Drug Design Scientific Advisory Board
Oxford Drug Design is pleased to announce the addition of Prof. David Livermore to our Scientific Advisory Board. David Livermore gained his […]
James B. Kahn, M.D. FIDSA, joins the Oxford Drug Design Scientific Advisory Board
Oxford Drug Design is pleased to announce the appointment of James B. Kahn, M.D. FIDSA, to the company’s Scientific Advisory Board. Dr. […]
InhibOx relauches as Oxford Drug Design
InhibOx has relaunched as Oxford Drug Design to reflect its transition to a biotechnology company focused on internal drug discovery. Our lead […]